Synopsis
Synopsis
0
KDMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
2. Calipsol
3. Calypsol
4. Ci 581
5. Ci-581
6. Ci581
7. Kalipsol
8. Ketalar
9. Ketamine
10. Ketanest
11. Ketaset
1. 1867-66-9
2. Vetalar
3. Ketaset
4. Ketalar
5. Ketamine Hcl
6. Ketanest
7. Ketolar
8. 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
9. Cl 369
10. Cn-52,372-2
11. (+-)-ketamine Hydrochloride
12. Ci-581
13. Ketamine Hydrochloride Ciii
14. Ketamine (as Hydrochloride)
15. O18yuo0i83
16. Calipsol
17. Kalipsol
18. Ketavet
19. (+-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
20. Cl-369
21. Dea No. 7285
22. Cn-523722
23. 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one;hydrochloride
24. Cn-52372-2
25. Ketamine Chloride
26. Ketavet 100
27. Ketavet (veterinary)
28. Ci 581
29. Chebi:650657
30. Einecs 217-484-6
31. Unii-o18yuo0i83
32. Ketalar (tn)
33. Ketamini Hydrochloridum
34. Ketamine Hydrochloride [usan:usp:jan]
35. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride
36. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+-)-
37. Ec 217-484-6
38. Chembl1714
39. Schembl26999
40. Dtxsid4040137
41. Ketamine Hydrochloride [mi]
42. 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one Hydrochloride
43. Bcp25943
44. Ketamine Hydrochloride (jp17/usp)
45. Ketamine Hydrochloride [jan]
46. (+/-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
47. Ketamine Hydrochloride [usan]
48. Nsc116131
49. (+/-)-ketamine Hydrochloride, Solid
50. Ketamine Hydrochloride [vandf]
51. Akos005287313
52. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+-)-
53. Ketamine Hydrochloride [mart.]
54. Ab02117
55. Ketamine Hydrochloride [who-dd]
56. Ketamine Hydrochloride [who-ip]
57. Nsc-116131
58. Ketamine Hydrochloride [green Book]
59. Db-044614
60. Db-048467
61. Ketamine Hydrochloride [ep Impurity]
62. Ketamine Hydrochloride [orange Book]
63. Ketamine Hydrochloride [ep Monograph]
64. Ketamine Hydrochloride Ciii [usp-rs]
65. Ketamine Hydrochloride [usp Monograph]
66. Ketamini Hydrochloridum [who-ip Latin]
67. C07843
68. D00711
69. 867k669
70. A813079
71. Q-201266
72. Q27105184
73. Ketamine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
74. 2-(2-chlorophenyl)-2-(methylamino)-1-cyclohexanone Hydrochloride
75. Ketamine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
76. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride (1:1)
77. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+/-)-
78. Ketamine (+-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanonehydrochloride
79. Ketamine Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 274.18 g/mol |
---|---|
Molecular Formula | C13H17Cl2NO |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 2 |
Exact Mass | 273.0687196 g/mol |
Monoisotopic Mass | 273.0687196 g/mol |
Topological Polar Surface Area | 29.1 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 269 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Ketalar |
Drug Label | Ketalar is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection in concentrat... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
2 of 4 | |
---|---|
Drug Name | Ketamine hydrochloride |
PubMed Health | Ketamine (Injection) |
Drug Label | Ketamine hydrochloride is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injectio... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Hospira; Mylan Institutional; Eurohlth Intl |
3 of 4 | |
---|---|
Drug Name | Ketalar |
Drug Label | Ketalar is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection in concentrat... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
4 of 4 | |
---|---|
Drug Name | Ketamine hydrochloride |
PubMed Health | Ketamine (Injection) |
Drug Label | Ketamine hydrochloride is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injectio... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Hospira; Mylan Institutional; Eurohlth Intl |
Anesthetics, Dissociative
Intravenous anesthetics that induce a state of sedation, immobility, amnesia, and marked analgesia. Subjects may experience a strong feeling of dissociation from the environment. The condition produced is similar to NEUROLEPTANALGESIA, but is brought about by the administration of a single drug. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) (See all compounds classified as Anesthetics, Dissociative.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Excitatory Amino Acid Antagonists
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Ketamine Hydrochloride BP/EP/USP
Date of Issue : 2022-06-29
Valid Till : 2025-07-02
Written Confirmation Number : WC-0218n
Address of the Firm : A-5/2, Late Parshuram Industrial Area, MIDC, Tal-Khed, Dist. Ratnagiri-415 722, ...
Date of Issue : 2024-11-13
Valid Till : 2027-11-12
Written Confirmation Number : WC-0596
Address of the Firm : Sarmastapur, Polghat Panchayat P.S., Sonarpur Kolkata, South 24 Parganas-700145,...
Ketamine Hydrochloride USP/Ph.Eur
Date of Issue : 2024-02-12
Valid Till : 2027-02-11
Written Confirmation Number : WC-0407
Address of the Firm : Sy. No. 205, 222 to 226, IDA Bonthapally, Bonthapally (Village), Gummadidala (Ma...
Date of Issue : 2023-04-18
Valid Till : 2026-04-17
Written Confirmation Number : WC-0557
Address of the Firm : Plot No. 69/A, GIDC Industrial Estate, Vapi, Dist?Valsad 396195, Gujarat, India
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
R-107 Depression Study Results Published in Nature Medicine
Details : R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 25, 2024
Details:
R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance dosing.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 26, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107
Details : R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance ...
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 26, 2023
Details:
R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial Data Suggests Major Breakthrough in Treatment Resistant Depression
Details : R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 15, 2021
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, being investigated for the management of pain, depression etc.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaTher’s Ketamine Review Extended by FDA with New Goal Set for Aug 2025
Details : Ketarx (ketamine) is a NMDA receptor antagonist, being investigated for the management of pain, depression etc.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 16, 2025
Details:
ALA-3000, developed by Alar Pharmaceuticals, is the first formulation of ketamine lasting over one week in the blood following single dose and is being developed for Treatment-Resistant Depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: ALA-3000
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alar Doses First Patient in ALA-3000 Study for Treatment-Resistant Depression
Details : ALA-3000, developed by Alar Pharmaceuticals, is the first formulation of ketamine lasting over one week in the blood following single dose and is being developed for Treatment-Resistant Depression.
Product Name : ALA-3000
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 14, 2025
Details:
SP-26 is a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Musculoskeletal Brand Name: SP-26
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Details : SP-26 is a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 30, 2025
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaTher Receives US FDA Approval Goal Date for Ketamine
Details : Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 11, 2025
Details:
Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketamir-2
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Starts Phase 1 Trial for Ketamir-2 in Neuropathic Pain
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2025
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaTher Provides Update on FDA New Drug Application for Ketamine
Details : Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 12, 2025
Details:
SP-26 is a ketamine HCl-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Musculoskeletal Brand Name: SP-26
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma Reports Positive SP-26 Study for Chronic Pain & Fibromyalgia
Details : SP-26 is a ketamine HCl-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 11, 2025
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 100MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Norway
Brand Name : Ketamin Abcur
Dosage Form : Injection fluid, resolution
Dosage Strength : 10 mg/ml
Packaging : Ampoule of glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : RX
Registration Country : USA
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 10MG BASE/ML
Packaging :
Approval Date : 2008-09-30
Application Number : 76092
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : KETALAR
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 100MG BASE/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 16812
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 50MG BASE/ML
Packaging :
Approval Date : 2023-01-13
Application Number : 215808
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Ketamine 10mg/1ml Fresenius
Dosage Form : INJ
Dosage Strength : 10mg/ml
Packaging : 20X10mg/ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info :
Registration Country : Sweden
Brand Name : Ketalar
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 50 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 50MG BASE/ML
Approval Date : 2023-01-13
Application Number : 215808
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 100MG BASE/ML
Approval Date : 2025-04-18
Application Number : 215808
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 10MG BASE/ML
Approval Date : 2023-01-24
Application Number : 216809
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 50MG BASE/ML
Approval Date : 2023-01-24
Application Number : 216809
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 100MG BASE/ML
Approval Date : 2023-01-24
Application Number : 216809
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 50MG BASE/ML
Approval Date : 1996-03-22
Application Number : 74524
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 100MG BASE/ML
Approval Date : 1996-03-22
Application Number : 74524
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : KETAMINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 50MG BASE/ML
Approval Date : 1996-06-27
Application Number : 74549
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD :
TE Code :
Brand Name : KETAMINE HCL
Dosage Form : Injectable; Injection
Dosage Strength : EQ 10MG BASE/ML
Approval Date :
Application Number : 71949
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : KETAMINE HCL
Dosage Form : Injectable; Injection
Dosage Strength : EQ 50MG BASE/ML
Approval Date :
Application Number : 71950
RX/OTC/DISCN :
RLD :
TE Code :
Regulatory Info :
Registration Country : Norway
Brand Name : Ketamin Abcur
Dosage Form : Injection fluid, resolution
Dosage Strength : 10 mg/ml
Packaging : Ampoule of glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Ketamin Abcur
Dosage Form : Injection fluid, resolution
Dosage Strength : 50 mg/ml
Packaging : Ampoule of glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : Ketamine
Dosage Form : Ketamine 100Mg 2Ml 5 Units Parenteral Use
Dosage Strength : 5 vials 2ml 50 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Brand Name : Ketalar
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 50 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Ketalar
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 10 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Ketanest-S
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 25 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Ketanest-S
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 5 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Ketalar
Dosage Form : Injection fluid, resolution
Dosage Strength : 10 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Ketalar
Dosage Form : Injection fluid, resolution
Dosage Strength : 50 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Ketalar
Dosage Form : Solution for injection
Dosage Strength : 50 mg/ml
Packaging : Vials 10ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
86
PharmaCompass offers a list of Ketamine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ketamine Hydrochloride manufacturer or Ketamine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ketamine Hydrochloride manufacturer or Ketamine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ketamine Hydrochloride API Price utilized in the formulation of products. Ketamine Hydrochloride API Price is not always fixed or binding as the Ketamine Hydrochloride Price is obtained through a variety of data sources. The Ketamine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ketamine HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ketamine HCl, including repackagers and relabelers. The FDA regulates Ketamine HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ketamine HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ketamine HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ketamine HCl supplier is an individual or a company that provides Ketamine HCl active pharmaceutical ingredient (API) or Ketamine HCl finished formulations upon request. The Ketamine HCl suppliers may include Ketamine HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Ketamine HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ketamine HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Ketamine HCl active pharmaceutical ingredient (API) in detail. Different forms of Ketamine HCl DMFs exist exist since differing nations have different regulations, such as Ketamine HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ketamine HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Ketamine HCl USDMF includes data on Ketamine HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ketamine HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ketamine HCl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ketamine HCl Drug Master File in Japan (Ketamine HCl JDMF) empowers Ketamine HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ketamine HCl JDMF during the approval evaluation for pharmaceutical products. At the time of Ketamine HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ketamine HCl suppliers with JDMF on PharmaCompass.
A Ketamine HCl CEP of the European Pharmacopoeia monograph is often referred to as a Ketamine HCl Certificate of Suitability (COS). The purpose of a Ketamine HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ketamine HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ketamine HCl to their clients by showing that a Ketamine HCl CEP has been issued for it. The manufacturer submits a Ketamine HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ketamine HCl CEP holder for the record. Additionally, the data presented in the Ketamine HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ketamine HCl DMF.
A Ketamine HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ketamine HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ketamine HCl suppliers with CEP (COS) on PharmaCompass.
A Ketamine HCl written confirmation (Ketamine HCl WC) is an official document issued by a regulatory agency to a Ketamine HCl manufacturer, verifying that the manufacturing facility of a Ketamine HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ketamine HCl APIs or Ketamine HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Ketamine HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Ketamine HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ketamine HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ketamine HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ketamine HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ketamine HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ketamine HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ketamine HCl suppliers with NDC on PharmaCompass.
Ketamine HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ketamine HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ketamine HCl GMP manufacturer or Ketamine HCl GMP API supplier for your needs.
A Ketamine HCl CoA (Certificate of Analysis) is a formal document that attests to Ketamine HCl's compliance with Ketamine HCl specifications and serves as a tool for batch-level quality control.
Ketamine HCl CoA mostly includes findings from lab analyses of a specific batch. For each Ketamine HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ketamine HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Ketamine HCl EP), Ketamine HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ketamine HCl USP).